NCIt definition : A T-cell receptor (TCR)-like T-cell engaging bispecific antibody (T-BsAb) targeting
both the RMFPNAPYL nonapeptide (RMF peptide), which is derived from the intracellular
Wilms tumor 1 (WT1; WT-1) and presented on human leukocyte antigen A2 (HLA-A2), and
the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic
activities. Upon administration, anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific
antibody RO7283420 simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs)
and the HLA-A2 WT1 complex found on WT1-expressing tumor cells. This activates and
redirects CTLs to WT1-expressing tumor cells, which results in the CTL-mediated cell
death of WT1-expressing tumor cells. WT1, an intracellular oncoprotein and transcription
factor, is overexpressed in a variety of tumor cell types.;
Molecule name : RG-06007; RO-7283420; RO 7283420; RG 6007; RG6007;
Semantic type(s)